MA54937A - Troubles induits par l'interféron de type i - Google Patents

Troubles induits par l'interféron de type i

Info

Publication number
MA54937A
MA54937A MA054937A MA54937A MA54937A MA 54937 A MA54937 A MA 54937A MA 054937 A MA054937 A MA 054937A MA 54937 A MA54937 A MA 54937A MA 54937 A MA54937 A MA 54937A
Authority
MA
Morocco
Prior art keywords
interferon type
disorders induced
disorders
induced
interferon
Prior art date
Application number
MA054937A
Other languages
English (en)
Inventor
Kerry Casey
Miguel Sanjuan
Dominic Sinibaldi
Michael Smith
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA54937A publication Critical patent/MA54937A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA054937A 2019-02-15 2020-02-14 Troubles induits par l'interféron de type i MA54937A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962806002P 2019-02-15 2019-02-15

Publications (1)

Publication Number Publication Date
MA54937A true MA54937A (fr) 2021-12-22

Family

ID=69591655

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054937A MA54937A (fr) 2019-02-15 2020-02-14 Troubles induits par l'interféron de type i

Country Status (13)

Country Link
US (1) US20220162325A1 (fr)
EP (1) EP3924383A1 (fr)
JP (1) JP7522749B2 (fr)
KR (1) KR20210131354A (fr)
CN (1) CN113508138B (fr)
AU (1) AU2020222262B2 (fr)
BR (1) BR112021015596A2 (fr)
CA (1) CA3128785A1 (fr)
EA (1) EA202192176A1 (fr)
IL (1) IL285321A (fr)
MA (1) MA54937A (fr)
SG (1) SG11202108679PA (fr)
WO (1) WO2020165437A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020382850A1 (en) * 2019-11-11 2022-06-23 Astrazeneca Ab Type I interferon inhibition in systemic lupus erythematosus
ES2963757T3 (es) 2021-04-23 2024-04-01 Astrazeneca Ab Régimen de dosificación de anti-ifnar1 para inyección subcutánea

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US941004A (en) 1906-03-24 1909-11-23 Brandt Cashier Company Calculating implement.
WO1984003106A1 (fr) 1983-02-04 1984-08-16 Wadley Inst Of Molecular Medic Production et caracterisation d'anticorps d'hybridomes diriges specifiquement contre un/des determinant(s) commun(s) present(s) parmi des proteines en relation etroite mais distinctes
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
DE3685996T2 (de) 1985-06-11 1993-01-14 Ciba Geigy Ag Hybrid-interferone.
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US7619070B2 (en) 2003-04-23 2009-11-17 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
LT2662390T (lt) 2004-06-21 2017-10-10 E. R. Squibb & Sons, L.L.C. Interferono-alfa receptoriaus-1 antikūnai ir jų panaudojimas
AU2007327993B2 (en) 2006-12-06 2013-06-20 Medimmune, Llc. Methods of treating systemic lupus erythematosus
PL2250279T3 (pl) 2008-02-08 2016-11-30 Przeciwciała anty-ifnar1 o zmniejszonym powinowactwie do liganda fc
MX2012002640A (es) * 2009-09-03 2012-06-25 Medimmune Llc Diagnostico de interferon tipo 1.
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑

Also Published As

Publication number Publication date
CN113508138A (zh) 2021-10-15
WO2020165437A1 (fr) 2020-08-20
AU2020222262B2 (en) 2024-06-20
SG11202108679PA (en) 2021-09-29
EP3924383A1 (fr) 2021-12-22
JP2022520417A (ja) 2022-03-30
CN113508138B (zh) 2024-08-09
IL285321A (en) 2021-09-30
KR20210131354A (ko) 2021-11-02
US20220162325A1 (en) 2022-05-26
AU2020222262A1 (en) 2021-09-30
BR112021015596A2 (pt) 2021-10-05
EA202192176A1 (ru) 2022-01-13
CA3128785A1 (fr) 2020-08-20
JP7522749B2 (ja) 2024-07-25

Similar Documents

Publication Publication Date Title
MA51203A (fr) Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline
MA54521A (fr) Dérivés d'oxopyridine substitués
MA54937A (fr) Troubles induits par l'interféron de type i
MA52801A (fr) Conjugués oligomères à saut d'exon pour dystrophie musculaire
MA55010A (fr) Système d'électrodes
MA54744A (fr) Support autoligaturant pour l'orthodontie
GB201915753D0 (en) Alzheimer's disease
GB201820756D0 (en) MJ's-vimana
IT201800003758U1 (it) "modello di contratto per la fornitura di servizi di manutenzione"
IT201700035964A1 (it) “divisorio per boiserie”
UA40267S (uk) Гайка з'єднувальна
ES1261716Y (es) "cubrecajas"
UA41001S (uk) Пляшка «buvette»
UA39991S (uk) Опаковання-етикетка для печива «tet-a-tet»
IT201900021909A1 (it) Stampella ortopedica elettromeccanica "pinfarina"
GB201908319D0 (en) Pionka's truffin
UA38418S (uk) Акустична система «імперія»
UA39688S (uk) Набір бокалів «top design»
UA41363S (uk) Комплект лінійок-трафаретів «дорожній трафік»
UA40970S (uk) Вертикальний профіль «стійка ст-6.2»
UA41233S (uk) Статуетка «дюк де рішельє»
RU2018109972A (ru) Пептид, обладающий лечебным действием против болезни Альцгеймера
UA41867S (uk) Чашка «classic»
UA41598S (uk) Наголовний убор дитячий «шапка-бант»
UA40693S (uk) Набір етикеток на пляшку «карпатське»